7 Hills Pharma Safely Doses First Patient in Phase 1b/2a Clinical Trial Testing Alintegimod Against aPD-1-resistant Solid Tumors
September 03, 2024 14:02 ET
|
7 Hills Pharma
7 Hills safely doses first cancer patient with alintegimod, a novel selective integrin activator designed to improve the efficacy of checkpoint blockade.
7 Hills Pharma Receives $4.7MM Grant to Advance First-in-class Cell/Gene Therapy Technology into the Clinic
June 03, 2024 12:57 ET
|
7 Hills Pharma
Houston biotech awarded $4.7MM in homegrown Texas support for new technology to safely improve the treatment of advanced blood cancers and genetic diseases
7 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding
May 22, 2023 13:05 ET
|
7 Hills Pharma
HOUSTON, May 22, 2023 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”) announced today that it has been awarded $13.5MM in nondilutive grant funds from the Cancer Prevention &...
7 Hills Pharma Receives $3MM SBIR Grant from NIAID to Accelerate Novel Vaccine Combination Against Chagas Disease
August 01, 2022 05:00 ET
|
7 Hills Pharma
HOUSTON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”), a clinical-stage pharma company developing a platform of first-in-class oral small molecules to enhance the...
7 Hills Pharma Expands Pioneering Patent Portfolio With New Claims Covering Innovative Combination Therapies
June 09, 2022 19:53 ET
|
7 Hills Pharma
HOUSTON, June 09, 2022 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”) has secured newly issued US patent claims that significantly expand the extent of the company’s intellectual...
New Study Demonstrates Integrin Activation Can Bring the Heat to Cold Melanoma Tumors
May 18, 2022 19:23 ET
|
7 Hills Pharma
HOUSTON, May 18, 2022 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”), together with The University of Texas MD Anderson Cancer Center (“MD Anderson”) and Texas Heart Institute (“THI”),...
7 Hills Pharma’s Clinical-stage Novel Immunostimulant 7HP349 Granted FDA Fast Track Designation for Anti-PD-1-resistant Metastatic Melanoma
March 08, 2022 17:32 ET
|
7 Hills Pharma
HOUSTON, March 08, 2022 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”), a clinical-stage drug development company bringing to market a platform of unique, first-in-class oral small...
7 Hills Pharma Announces the Completion of a Landmark Phase I Trial of Immunostimulant to Improve Immuno-Oncology Drugs, COVID-19 and Influenza Vaccines
November 01, 2021 15:08 ET
|
7 Hills Pharma
HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”), a clinical-stage drug development company bringing to market a platform of unique, first-in-concept oral small...
Texas Heart Institute, University of Texas Medical Branch (UTMB) and 7 Hills Pharma Pioneer Significant Vaccine Research
October 01, 2021 14:59 ET
|
7 Hills Pharma
HOUSTON, TX., Oct. 01, 2021 (GLOBE NEWSWIRE) -- The Texas Heart Institute has announced that a research team led by its Vice President for Research Dr. Darren Woodside and Dr. Peter Vanderslice, of...
7 Hills Pharma Names Biopharma Industry Veteran Michael S. Perry Chairman of its Board of Managers
July 26, 2021 07:00 ET
|
7 Hills Pharma
HOUSTON, July 26, 2021 (GLOBE NEWSWIRE) -- 7 Hills Pharma, a clinical stage immunotherapy company focused on the development of drugs for treatment and prevention of cancer and infectious diseases,...